Isomorphic Labs in Early Funding Talks at $40B Valuation
- Company
- Isomorphic Labs
- Funding stage
- Undisclosed
- Amount
- Undisclosed
- Date
- Location
- 🇺🇸 the US
- Sector
- Drug Discovery
- Investors
- Undisclosed
What happened
Isomorphic Labs is in early talks to raise new funding at a valuation of at least $40 billion. The AI-powered drug discovery startup was spun out of Alphabet Inc.’s Google DeepMind.
Why it matters
A $40 billion target valuation for an AI drug discovery firm establishes a high pricing ceiling for DeepMind spinouts. Strategic AI spin-offs continue to command sovereign-scale valuations ahead of potential public listings.
What to watch
Whether external institutional investors validate the $40 billion price tag or if Alphabet remains the primary funding source.
VCBites Signal
Why this score: A target valuation of at least $40 billion for an Alphabet spinout reflects peak market willingness to price AI-native biopharma platforms as category-defining infrastructure.
VCBites' internal significance rating (0-100) — our editorial read, not a market-standard metric. VC Bites' assessment of the significance of this development to the venture ecosystem. Not investment advice.
Who should care?
- Biotech Founders
- AI Investors
- Pharma Executives
- Growth Investors
Source
This is an original short summary. Read the full reporting at the original source.
Read the original story on BloombergShare the signal
VC Bites
Isomorphic Labs in Early Funding Talks at $40B Valuation
VCBITES SIGNAL: 60 / 100
Why it matters
A $40 billion target valuation for an AI drug discovery firm establishes a high pricing ceiling for DeepMind spinouts. Strategic AI spin-offs continue to command sovereign-scale valuations ahead of potential public listings.
VC Bites · Venture capital signals, explained.
The post text is copied to your clipboard so you can paste it alongside the link.